Stock Selection: Kimi's picks for 2026-09-23

Kimi picked META, MSFT, NVDA, AMD, LLY for a 1-day horizon. Portfolio return vs SPY: +0.92%. Picks that beat SPY: 60%.

ExperimentStock Selection
ModelKimi
Prompt versionstock-selection-v8
Asked
Horizon1-day
Measured from2026-09-23
Measured to2026-09-24
BenchmarkSPY
StatusSettled
Portfolio return vs SPY+0.92%
Picks that beat SPY60%
Benchmark return-0.70%

The picks

RankSymbolReturnConfidencevs benchmarkCalled right
1META+1.10%78%+1.80%Yes
2MSFT-0.70%72%-0.00%No
3NVDA-1.57%68%-0.87%No
4AMD-0.45%64%+0.25%Yes
5LLY+2.71%62%+3.41%Yes

The model's market view

The Fed's first rate hike in three years on Sept 16 (to 3.75%-4.00%) with hawkish guidance from Chair Warsh has created a cautious tape, with SPY down ~0.6% intraday on Sept 23 near $769. Tech semis are under pressure (NVDA -1.5%, AMD -1.6%, AVGO -2.2%), while select names with idiosyncratic catalysts and quality attributes are bucking the trend. For a 1-day horizon, I favor stocks with positive momentum, event-driven catalysts, and analyst support that can decouple from index-level rate-hike digestion.

Why each pick

META

Meta is hosting its Connect event today (Sept 23), where new AI products and hardware including AI glasses are expected, serving as a strong idiosyncratic catalyst. The stock is up ~2.6% intraday, bucking the weak tape, and analysts see upside toward $800 (~19% above prior levels). Strong buy consensus (1.3 rating, 56 analysts). Risks: event-driven volatility if product announcements disappoint, high beta to any hawkish Fed repricing, Reality Labs spending concerns.

MSFT

Microsoft is one of the few mega-caps trading positive today (+0.2% intraday), showing relative strength in a hawkish-Fed tape. Strong buy consensus (1.3 rating, 52 analysts) with a mean target of $577 (~16% upside). Azure cloud and AI backlog provide durable earnings visibility that insulates it from rate-hike digestion better than most. Risks: high AI capex scrutiny, regulatory pressure on cloud licensing, broad tech de-rating if yields rise further.

NVDA

NVIDIA is down ~1.5% intraday, offering a dip-buy entry into a strong buy-rated name (1.3 consensus, 59 analysts, mean target $328, ~45% upside). Recent news highlights an immense dividend hike, putting dividend-growth focus on the stock, and the company has strong visibility into $1T+ AI demand through 2027 with Vera Rubin ramping. Mean reversion potential after a ~1.5% single-day decline in a still-upward trend. Risks: hawkish Fed pressure on high-multiple tech, China export restrictions, AI-capex sustainability debate.

AMD

AMD is down ~1.6% intraday, creating a short-term entry into a strong buy-rated semi (1.5 consensus, 50 analysts, mean target $617). Q2 FY2026 revenue grew >50% YoY with data center sales accelerating into late 2026; analysts expect >40% growth in 2026. High-beta name that typically outperforms on any dovish surprise or AI-sector bounce. Risks: hawkish Fed disproportionately hits high-multiple semis, Nvidia's GPU dominance, TSMC supply-chain geopolitics.

LLY

Eli Lilly offers defensive-growth characteristics in a rising-rate environment, with Mounjaro/Zepbound obesity-drug momentum driving ~48% revenue growth. Buy-rated (1.6 consensus, 29 analysts, mean target $1325, ~14% upside). Healthcare has been a relative safe haven during the current Fed-hike digestion, and LLY's growth profile justifies premium valuation. Down ~1% intraday, providing entry. Risks: premium valuation compression under higher rates, drug pricing policy risk, competition from Novo Nordisk.

Other models on the same run

ModelPicksPortfolio return vs SPYPicks that beat SPY
Claude Opus 5XLE, OIH, XOM, VKTX, XLV-1.92%80%
Muse Spark 1.1IONQ, MSFT, SOXL, NVDA, GOOG-1.01%0%
Gemini 1.5 ProNVDA, MSFT, SOXL, GOOG, AAPL-0.87%20%
Grok 4.5IONQ, PLTR, MU, AMD, NVDA-0.25%40%
GPT-6IONQ, CTAS, WOR, NVDA, UAL-1.23%0%
DeepSeekIONQ, MRNA, PLTR, CBRL, FUN+1.84%80%

Written up on ForecastNest Insights: Stock Selection: Kimi's picks for 2026-09-23.

ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.